

EQA round: KD2/24 - Glycated Haemoglobin

Deadline: 5.4.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]		
							AV	U _{AV}	D _{max}	LL	UL					
(220) Haemoglobin A_{1c}	[mmol/mol]				150							150	143	95		
Sample A		59,9	2,6	4,3	150		CVP	59,9	0,52	10%	53,9	65,9	150	143	95	
(14) Bio-Rad		60,6	2,1	3,4	44	0							44			
(25) TOSOH		60,5	1,3	2,1	37	0							37			
(34) Sebia		59,5	0,74	1,2	9	0							9			
(60) Roche		63	3	4,7	8	0							8			
(150) Arkray		57,6	1,8	3,1	42	0							42			
Other					10	0							10			
							1x 1, 3x 46, 3x 58, 1x 162, 1x 177, 1x 999									
Sample B		43,4	1,9	4,5	150		CVP	43,4	0,39	10%	39	47,8	150	146	97	
(14) Bio-Rad		43,2	1,4	3,3	44	0							44			
(25) TOSOH		44,7	0,97	2,2	37	0							37			
(34) Sebia		43,5	0,74	1,7	9	0							9			
(60) Roche		44	2,9	6,6	8	0							8			
(150) Arkray		42	1,4	3,3	42	0							42			
Other					10	0							10			
							1x 1, 3x 46, 3x 58, 1x 162, 1x 177, 1x 999									